Author

N. Hosseini

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Approach:experimental assay· 1

Frequent Co-Authors

A. Banito· 1 shared A. C. Faber· 1 shared A. Chinnaiyan· 1 shared A. Jose· 1 shared A. M. Stamatouli· 1 shared A. Parolia· 1 shared A. Poklepovic· 1 shared A. Sotiriou· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Banito

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma

K. V. Floros, C. K. Fairchild, J. Li, K. Zhang, J. L. Roberts, R. Kurupi, B. Hu, V. Kraskauskiene, N. Hosseini, S. Shen, M. M. Inge, K. Smith-Fry, L. Li, A. Sotiriou, K. M. Dalton, , A. C. Faber

This study shows that inhibiting SUMOylation with TAK-981 stabilizes cBAF complexes and disrupts the SS18::SSX-driven transcriptome in synovial sarcoma, leading to tumor inhibition.

bioRxiv · Apr 25, 2024 · PreprintCancer Biology

Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors

M. B. Mumphrey, N. Hosseini, A. Parolia, J. Geng, W. Zou, M. Raghavan, A. Chinnaiyan, M. Cieslik

The paper identifies distinct mutational processes in MHC class I and II genes across primary and metastatic tumors, showing positive selection for mutations disrupting immune interfaces and linking them to immune checkpoint inhibitor response.

bioRxiv · Jan 22, 2023Cancer Biology